Shares of Ranbaxy Laboratories gained 5.63 per cent to end at Rs 859.90 on the BSE. During the day, it soared 6.74 per cent to Rs 869 -- its 52-week high.
Sun Pharmaceutical Industries also rose by 5.51 per cent to settle at Rs 1,078.55. The stock was the top gainer among the 30-Sensex scrips.
Today was the last trading session for shares of Ranbaxy as domestic indices are closed tomorrow and day after for Mahavir Jayanti and Good Friday, respectively.
Sun Pharma has fixed April 7 as the record date for determining the entitlement of Ranbaxy shareholders to the equity shares of the former.
"Following the closure of this transaction, Ranbaxy will be delisted from the Indian Stock Exchanges. Ranbaxy shareholders will receive 0.8 share of Sun Pharma for each share of Ranbaxy," Sun Pharma had said in filing to the BSE last week.
In April 2014, Sun Pharma had announced it would acquire Ranbaxy in an all-stock transaction worth USD 4 billion that includes USD 800 million debt.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
